Riding the First Wave: Wegovy® and Zepbound® 🏄 GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023, due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they …
Continue reading “The Next Wave of Obesity Drugs: Opportunities and Risks for Investors 🌊”
